Jilin University
Also known as: 13.The Second Hospital of Jilin University | 2nd Floor, Building 1, No. 71, Xinmin Street, Changchun, Jilin Province | Affiliated Hospital of Jilin University, Changchun,China | Aiping Shi | China-japan Friendship Hospital, Jilin University | China-Japan Union Hospital, Jilin University | Di Wu | Dong Yang | First Affiliated Hospital of Jilin University | First Hospital Jilin University | First Hospital, Jilin University | First Hospital of Jilin Univerisity | First Hospital of Jilin University | Foshan University Laboratory of Emerging Infectious Disease Institute of Translational Medicine , Jilin University China | Jian Suo | Jilin Central General Hospital | Jilin hematology hospital | Jilin Provincal Cancer Hospital | Jilin Province Cancer Hospital | Jilin University | Jilin University First Affiliated Hospital | Jilin University First Hospital | Jilin University Medical Science Division | jiuwei cui | Junqi Niu | Neuroscience Center, Department of Neurology, The First Hospital of Jilin University | oubai, MD/PhD | Phase I Clinical Trial Laboratory,The First Hospital of Jilin University | Phase I Clinical Trial Unit, The First Hospital of Jilin University | Pneumology Department, The First Hospital of Jilin University | Quan Wang | Second Hospital of Jilin University | the Cancer Center of First Hospital of Jilin University | the chief of the neurology department, the First Hospital of Jilin University | The first affiliated hospital of Jilin University | The First Affiliated Hospital of Jilin University | The First Affiliated Hospital of Jilin University (Shouchun Wang) | The First Hospital of Jilin University, Jilin Province | The Second Norman Bethune Hospital of Jilin University | Xiaobo Yang, MD | Yi Yang
Highest phase reached
Phase 4
First clinical trial
Mar 1, 2007Last known activity
Apr 1, 2025
Timeline
1940s
- Jun 1, 1946
Jilin University— Founded
Drugs by trial phase (172 distinct, 160 trials)
Phase 4 (28 own, 0 via acquisition)
Phase 3 (50 own, 0 via acquisition)
Phase 2 (47 own, 0 via acquisition)
Phase 1 (21 own, 0 via acquisition)
Indications
Studied for
- Anovulation
- Arteriosclerosis
- Arteriosclerosis Obliterans
- Arthritis
- Arthritis, Rheumatoid
- Ascites
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Ductal, Breast
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Cerebral Infarction
- Colorectal Neoplasms
- Communicable Diseases
- Coronary Artery Disease
- Coronary Disease
- Dementia
- Dementia, Vascular
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dwarfism
- Dwarfism, Pituitary
- Endocrine System Diseases
- Fatty Liver
- Femur Head Necrosis
- Gallbladder Neoplasms
- Gonadal Dysgenesis
- Gout
- Heart Failure
- Heart Failure, Systolic
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Herpesviridae Infections
- Histiocytoma, Malignant Fibrous
- Hyperphosphatemia
- Infarction
- Infections
- Inflammation
- Ischemia
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, B-Cell
- Leukemia, Large Granular Lymphocytic
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Melanoma
- Meningeal Carcinomatosis
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myocardial Ischemia
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Neutropenia
- Non-alcoholic Fatty Liver Disease
- Osteonecrosis
- Overweight
- Pelvic Infection
- Pelvic Inflammatory Disease
- Pelvic Pain
- Postoperative Pain
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Pulmonary Disease, Chronic Obstructive
- Rectal Neoplasms
- Recurrence
- Renal Insufficiency, Chronic
- Sarcoma
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Stroke
- Syndrome
- Turner Syndrome
- Uterine Cervical Neoplasms
- Virus Diseases
Recent trials (50)
- NCT06963112CollaboratorPhase 1Apr 1, 2025
- NCT06963112CollaboratorPhase 1Apr 1, 2025
- NCT06981390Sponsor investigatorN/AFeb 1, 2025
- NCT06981390Lead sponsorN/AFeb 1, 2025
- NCT06981390OfficialN/AFeb 1, 2025
- NCT06454461Sponsor investigatorN/ASep 1, 2024
- NCT06454461Lead sponsorN/ASep 1, 2024
- NCT06472232CollaboratorPhase 4Jun 18, 2024
- NCT06333821OfficialPhase 3Apr 1, 2024
- NCT06078969CollaboratorPhase 2Nov 1, 2023
- NCT06078839CollaboratorPhase 4Oct 1, 2023
- NCT05888350CollaboratorN/AJul 30, 2023
- NCT05892042Overall official - principal investigatorN/AMay 1, 2023
- NCT05892042Reponsible party - principal investigatorN/AMay 1, 2023
- NCT05892042Lead sponsorN/AMay 1, 2023
Details
- Founded
- Changchun, CN Jun 1, 1946
- Last known activity
- Apr 1, 2025